跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
From Molecule to Medicine: The Journey a Drug Must Survive

Why most candidates never reach a human

2 / 4
Notice what preclinical testing is really doing. It is not trying to show that the drug works in people, because that question cannot be answered yet. It is trying to show that giving this molecule to a human is defensible at all. So it checks safety in cells and animals, and it checks whether the molecule behaves in a living body the way the design assumed. The example is worth pausing on: a molecule can bind its target perfectly in a simulation and still be cleared from the bloodstream in minutes, never reaching the tissue it was designed for. That is not a flaw in the design logic. It is the difference between a model and a body, and it is why so many candidates stop here.
0:00 / 0:00

Preclinical testing takes the candidate molecule and studies it in cells and in animals. The aim is not to prove the drug works in people, which cannot be done yet, but to gather enough evidence that exposing humans is defensible. Two things are checked. First, safety: does the molecule damage the liver, heart, or other organs, and at what dose does harm appear? Second, behavior in a living system: is the molecule absorbed, does it reach the intended tissue, and does it stay in the body long enough to matter?

Most candidates fail here. A molecule that looked excellent in a computer model can turn out to be toxic, to be broken down too quickly, or to have no measurable effect in a living animal. Because this stage is comparatively cheap and involves no human risk, it is designed to catch those failures early, before the far more expensive human trials begin.

Suppose a designed molecule binds its target beautifully in a simulation. In animal testing it might be cleared from the bloodstream within minutes, so it never reaches the target tissue at a useful concentration. Nothing is wrong with the design logic; the molecule simply does not survive contact with a living body. That candidate is dropped, and the next one is tested.

上一页2 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion